AIM IMMUNOTECH INC stock forecast: up to 1.24 USD AIM stock price prognosis
Forecast for Fri 08 Jul 2022 price
AIM IMMUNOTECH INC stock price forecast for further price development up to 30.28% (time horizon: 1 day) and price target of 1.24 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) AIM IMMUNOTECH INC share price prediction for 2022-07-08 with daily closed price projections
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
Ampligen has not been approved by the FDA or marketed in the US. & We continue to pursue our Ampligen NDA, for the treatment of CFS with the FDA. & The product will be marketed by GP Pharm, our commercial partner in Latin America. Up to 24 patients to be enrolled. Protocol design and funding currently being finalized. & & & & People with ME/CFS are often not able to do their usual activities. This symptom is known as post-exertional malaise (PEM). There have been delays related to importing Ampligen to China. We will announce when the shipment for testing purposes has been completed. It is planned that the phase 1/2a study will enroll up to 44 patients in two stages. We reported in September 2020 that recruitment in the trial had begun. We are currently exploring an expansion of this relationship. & Such events could materially and adversely impact our operations. In addition, we have no basis for estimating when material net cash inflows may commence. The contracts augment our existing fill and finish capacity. The average daily trading volume of our common stock varies significantly. & ldquo;Business”, Part I; Item 3. & We have filed provisional patent applications related to the COVID-19 coronavirus.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 32.36/100
Good financial position.
Historical view, profit is growing.
Company revenue is not growing faster compared with the
Institutional ownership list is based on filling form information
AIM IMMUNOTECH INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for AIM IMMUNOTECH INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for AIM IMMUNOTECH INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for AIM IMMUNOTECH INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for AIM IMMUNOTECH INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for AIM IMMUNOTECH INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for AIM IMMUNOTECH INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for AIM IMMUNOTECH INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio